New combo therapy shows promise in brain cancer trial
NCT ID NCT05635734
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tested whether adding the drug azeliragon to standard radiation and chemotherapy (temozolomide) is safe and shows early signs of working in people with newly diagnosed glioblastoma, a fast-growing brain cancer. 33 participants received the combination. The main goals were to find the best dose and check for side effects. Results help guide future larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Clínic de Barcelona
Barcelona, Barcelona, 08036, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, 28041, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, Madrid, 28034, Spain
-
Hospital del Mar
Barcelona, Barcelona, 08003, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?